Who are Tinzaparin (Leo)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): nadroparin calcium-warfarin sequential anticoagulation, Intermediate dose nadroparin, Low dose nadroparin, LMWH+Folic acid, LMWH (Fragmin, dalteparin), (Arm Closed) Tinzaparin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tinzaparin-leo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tinzaparin (Leo) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tinzaparin (Leo) (Tinzaparin (Leo)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low molecular weight heparin. Area: Cardiovascular.

phase 3 Low molecular weight heparin Factor Xa, Thrombin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Tinzaparin (Leo) (Tinzaparin (Leo)) — Aalborg University Hospital. Tinzaparin is a low molecular weight heparin that acts as an anticoagulant by inhibiting factor Xa and thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tinzaparin (Leo) TARGET	Tinzaparin (Leo)	Aalborg University Hospital	phase 3	Low molecular weight heparin	Factor Xa, Thrombin
nadroparin calcium-warfarin sequential anticoagulation	nadroparin calcium-warfarin sequential anticoagulation	Qilu Hospital of Shandong University	marketed	Anticoagulant combination (LMWH + vitamin K antagonist)	Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Intermediate dose nadroparin	Intermediate dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (via antithrombin III enhancement)
Low dose nadroparin	Low dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa)
LMWH+Folic acid	LMWH+Folic acid	Omar Mamdouh Shaaban	marketed	Anticoagulant combination with vitamin supplement	Factor Xa, Thrombin (LMWH component); Dihydrofolate reductase (folic acid component)
LMWH (Fragmin, dalteparin)	LMWH (Fragmin, dalteparin)	McMaster University	phase 3	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa), Antithrombin III
(Arm Closed) Tinzaparin	(Arm Closed) Tinzaparin	University of Melbourne	phase 3	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low molecular weight heparin class)

Aalborg University Hospital · 1 drug in this class
Queen Mary University of London · 1 drug in this class
Rajaie Cardiovascular Medical and Research Center · 1 drug in this class
VarmX B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tinzaparin (Leo) — Competitive Intelligence Brief. https://druglandscape.com/ci/tinzaparin-leo. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing